NBIX vs. KNSL

Last updated Apr 2, 2026

Compare and contrast key facts about Neurocrine Biosciences, Inc. (NBIX) and Kinsale Capital Group, Inc. (KNSL).

Performance

NBIX vs. KNSL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Neurocrine Biosciences, Inc. (NBIX) and Kinsale Capital Group, Inc. (KNSL). The values are adjusted to include any dividend payments, if applicable.

NBIX vs. KNSL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NBIX Neurocrine Biosciences, Inc.	-6.54%	3.90%	3.60%	10.31%	40.24%	-11.14%	-10.83%	50.53%	-7.96%	100.49%
KNSL Kinsale Capital Group, Inc.	-11.53%	-15.78%	39.06%	28.27%	10.17%	19.16%	97.28%	83.67%	24.09%	33.20%

Fundamentals

Market Cap NBIX : $13.59B KNSL : $8.01B
EPS NBIX : $4.69 KNSL : $21.67
PE Ratio NBIX : 28.25 KNSL : 15.96
PEG Ratio NBIX : 0.56 KNSL : 0.42
PS Ratio NBIX : 4.73 KNSL : 4.29
PB Ratio NBIX : 4.18 KNSL : 4.09
Total Revenue (TTM) NBIX : $2.86B KNSL : $1.87B
Gross Profit (TTM) NBIX : $2.81B KNSL : $862.60M
EBITDA (TTM) NBIX : $719.10M KNSL : $644.95M

Returns By Period

In the year-to-date period, NBIX achieves a -6.54% return, which is significantly higher than KNSL's -11.53% return.

NBIX

• 1D: 0.62%
• 1M: 0.14%
• YTD: -6.54%
• 6M: -3.24%
• 1Y: 23.89%
• 3Y*: 9.41%
• 5Y*: 6.19%
• 10Y*: 12.30%

KNSL

• 1D: 1.21%
• 1M: -12.72%
• YTD: -11.53%
• 6M: -17.08%
• 1Y: -29.03%
• 3Y*: 5.00%
• 5Y*: 15.79%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NBIX vs. KNSL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NBIX

NBIX Risk / Return Rank: 61
NBIX Sharpe Ratio Rank: 66
NBIX Sortino Ratio Rank: 58
NBIX Omega Ratio Rank: 60
NBIX Calmar Ratio Rank: 61
NBIX Martin Ratio Rank: 62

KNSL

KNSL Risk / Return Rank: 9
KNSL Sharpe Ratio Rank: 9
KNSL Sortino Ratio Rank: 12
KNSL Omega Ratio Rank: 11
KNSL Calmar Ratio Rank: 10
KNSL Martin Ratio Rank: 5

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NBIX vs. KNSL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and Kinsale Capital Group, Inc. (KNSL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NBIX	KNSL	Difference
Sharpe ratio Return per unit of total volatility	0.71	-0.78	+1.49
Sortino ratio Return per unit of downside risk	1.13	-0.92	+2.05
Omega ratio Gain probability vs. loss probability	1.16	0.87	+0.29
Calmar ratio Return relative to maximum drawdown	0.95	-0.83	+1.78
Martin ratio Return relative to average drawdown	2.31	-1.67	+3.98
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NBIX vs. KNSL - Sharpe Ratio Comparison

The current NBIX Sharpe Ratio is 0.71, which is higher than the KNSL Sharpe Ratio of -0.78. The chart below compares the historical Sharpe Ratios of NBIX and KNSL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NBIX	KNSL	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.71	-0.78	+1.49
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.19	0.41	-0.22
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.31	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.13	0.94	-0.81

Correlation

The correlation between NBIX and KNSL is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NBIX vs. KNSL - Dividend Comparison

NBIX has not paid dividends to shareholders, while KNSL's dividend yield for the trailing twelve months is around 0.22%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
NBIX Neurocrine Biosciences, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
KNSL Kinsale Capital Group, Inc.	0.22%	0.17%	0.13%	0.17%	0.20%	0.18%	0.18%	0.31%	0.50%	0.53%	0.29%

Drawdowns

NBIX vs. KNSL - Drawdown Comparison

The maximum NBIX drawdown since its inception was -97.21%, which is greater than KNSL's maximum drawdown of -40.22%. Use the drawdown chart below to compare losses from any high point for NBIX and KNSL.

Drawdown Indicators

	NBIX	KNSL	Difference
Max Drawdown Largest peak-to-trough decline	-97.21%	-40.22%	-56.99%
Max Drawdown (1Y) Largest decline over 1 year	-20.90%	-34.84%	+13.94%
Max Drawdown (5Y) Largest decline over 5 years	-42.89%	-40.22%	-2.67%
Max Drawdown (10Y) Largest decline over 10 years	-46.39%	—	—
Current Drawdown Current decline from peak	-14.82%	-36.69%	+21.87%
Average Drawdown Average peak-to-trough decline	-44.05%	-11.34%	-32.71%
Ulcer Index Depth and duration of drawdowns from previous peaks	8.59%	17.25%	-8.66%

Volatility

NBIX vs. KNSL - Volatility Comparison

The current volatility for Neurocrine Biosciences, Inc. (NBIX) is 6.97%, while Kinsale Capital Group, Inc. (KNSL) has a volatility of 9.25%. This indicates that NBIX experiences smaller price fluctuations and is considered to be less risky than KNSL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NBIX	KNSL	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.97%	9.25%	-2.28%
Volatility (6M) Calculated over the trailing 6-month period	23.03%	25.67%	-2.64%
Volatility (1Y) Calculated over the trailing 1-year period	33.89%	37.47%	-3.58%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	32.22%	38.30%	-6.08%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	39.43%	38.32%	+1.11%

Financials

NBIX vs. KNSL - Profitability Comparison

The chart below illustrates the profitability comparison between Neurocrine Biosciences, Inc. and Kinsale Capital Group, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

NBIX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Neurocrine Biosciences, Inc. reported a gross profit of 787.90M and revenue of 805.50M. Therefore, the gross margin over that period was 97.8%.

KNSL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Kinsale Capital Group, Inc. reported a gross profit of 270.07M and revenue of 483.27M. Therefore, the gross margin over that period was 55.9%.

NBIX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Neurocrine Biosciences, Inc. reported an operating income of 210.90M and revenue of 805.50M, resulting in an operating margin of 26.2%.

KNSL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Kinsale Capital Group, Inc. reported an operating income of 174.82M and revenue of 483.27M, resulting in an operating margin of 36.2%.

NBIX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Neurocrine Biosciences, Inc. reported a net income of 153.70M and revenue of 805.50M, resulting in a net margin of 19.1%.

KNSL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Kinsale Capital Group, Inc. reported a net income of 138.62M and revenue of 483.27M, resulting in a net margin of 28.7%.